Seres Therapeutics (NASDAQ:MCRB) Cut to Sell at StockNews.com

Seres Therapeutics (NASDAQ:MCRB) was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Saturday.

Other equities research analysts have also recently issued research reports about the company. Canaccord Genuity Group reiterated a “buy” rating and issued a $10.00 price objective on shares of Seres Therapeutics in a report on Thursday, November 14th. JPMorgan Chase & Co. cut shares of Seres Therapeutics from a “neutral” rating to an “underweight” rating in a report on Thursday, October 24th. Finally, Chardan Capital restated a “buy” rating and issued a $1.25 price objective on shares of Seres Therapeutics in a report on Wednesday, November 13th. Two analysts have rated the stock with a sell rating, one has given a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $5.08.

Seres Therapeutics Trading Down 0.7 %

MCRB stock opened at $0.84 on Friday. The stock has a market capitalization of $144.15 million, a price-to-earnings ratio of -3.67 and a beta of 2.13. The firm’s 50-day moving average price is $0.83 and its two-hundred day moving average price is $0.90. Seres Therapeutics has a 12-month low of $0.54 and a 12-month high of $1.53.

Hedge Funds Weigh In On Seres Therapeutics

Several large investors have recently made changes to their positions in MCRB. Virtu Financial LLC boosted its holdings in Seres Therapeutics by 44.8% in the third quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company’s stock worth $56,000 after acquiring an additional 18,191 shares in the last quarter. Providence Wealth Advisors LLC grew its position in Seres Therapeutics by 29.2% during the 3rd quarter. Providence Wealth Advisors LLC now owns 98,500 shares of the biotechnology company’s stock valued at $93,000 after purchasing an additional 22,250 shares during the last quarter. State Street Corp increased its stake in Seres Therapeutics by 12.9% during the 3rd quarter. State Street Corp now owns 383,248 shares of the biotechnology company’s stock valued at $363,000 after purchasing an additional 43,700 shares in the last quarter. Point72 DIFC Ltd purchased a new position in Seres Therapeutics in the second quarter worth about $64,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Seres Therapeutics during the second quarter valued at approximately $92,000. 59.34% of the stock is currently owned by hedge funds and other institutional investors.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.